AnaptysBio (NASDAQ:ANAB) Insider Paul Lizzul Sells 2,235 Shares of Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Paul Lizzul sold 2,235 shares of the stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $45.11, for a total transaction of $100,820.85. Following the transaction, the insider owned 37,213 shares in the company, valued at approximately $1,678,678.43. The trade was a 5.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

AnaptysBio Stock Performance

Shares of AnaptysBio stock opened at $43.80 on Friday. The company has a market capitalization of $1.21 billion, a PE ratio of -15.53 and a beta of 0.32. The company has a 50-day simple moving average of $42.46 and a two-hundred day simple moving average of $31.30. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $52.47.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The business had revenue of $76.32 million for the quarter, compared to analyst estimates of $15.83 million. On average, equities analysts predict that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its board has approved a share repurchase plan on Friday, November 21st that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the biotechnology company to purchase up to 9.6% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its stock is undervalued.

More AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: UBS upgraded AnaptysBio to a “strong‑buy,” which can drive retail and institutional buying interest and lift short‑term momentum. UBS upgrade / coverage note
• Positive Sentiment: AnaptysBio filed a partial motion to dismiss Tesaro/GSK’s anticipatory‑breach claim related to Jemperli royalties; a successful dismissal would reduce legal and royalty exposure and improve free‑cash‑flow prospects tied to that program. AnaptysBio seeks partial dismissal in GSK dispute
• Negative Sentiment: CEO Daniel Faga sold about $662k of stock (9,202 shares), a disclosed insider sale that can raise investor concerns about insider conviction even though his remaining stake is still large. CEO stock sale article
• Negative Sentiment: Other insiders (CFO Dennis Mulroy, Paul Lizzul, Eric Loumeau and others) also sold shares in the same filing period — several sizable dispositions that increase selling pressure and may temper the upside from analyst upgrades or legal wins. SEC Form 4 filings detail these trades. SEC Form 4 filings (insider sales)

Institutional Investors Weigh In On AnaptysBio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANAB. Tudor Investment Corp ET AL boosted its stake in shares of AnaptysBio by 47.2% in the third quarter. Tudor Investment Corp ET AL now owns 13,869 shares of the biotechnology company’s stock worth $425,000 after buying an additional 4,450 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of AnaptysBio by 2.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 378,452 shares of the biotechnology company’s stock worth $11,588,000 after purchasing an additional 10,005 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of AnaptysBio during the 3rd quarter worth approximately $315,000. Larson Financial Group LLC increased its holdings in shares of AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares in the last quarter. Finally, Granahan Investment Management LLC lifted its stake in shares of AnaptysBio by 12.2% in the 3rd quarter. Granahan Investment Management LLC now owns 147,773 shares of the biotechnology company’s stock valued at $4,525,000 after purchasing an additional 16,118 shares during the period.

Analyst Ratings Changes

Several research firms have weighed in on ANAB. Wells Fargo & Company boosted their target price on shares of AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Wedbush reissued an “outperform” rating and set a $50.00 price objective on shares of AnaptysBio in a report on Monday, November 24th. HC Wainwright cut their target price on AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a research report on Monday, November 24th. Truist Financial raised their target price on AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research note on Monday, November 10th. Finally, UBS Group initiated coverage on AnaptysBio in a research note on Wednesday. They set a “buy” rating and a $70.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, AnaptysBio presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.40.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.